Tesamorelin vs SLU-PP-332
Side-by-side comparison of Tesamorelin and SLU-PP-332: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Tesamorelin
SLU-PP-332
Tesamorelin
Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically the full 44-amino-acid GHRH sequence with a single N-terminal trans-3-hexenoyl fatty-acid modification. That…
Lowest listed price: $44.99 across 5 listings
Full Tesamorelin profileSLU-PP-332
SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023…
Lowest listed price: $69.99 across 5 listings
Full SLU-PP-332 profileSide-by-side comparison
| Attribute | Tesamorelin | SLU-PP-332 |
|---|---|---|
| Category | Growth Hormone / IGF-1 Axis | Performance |
| Research Stage | FDA Approved | Preclinical |
| Mechanism of Action | Tesamorelin activates the same GHRH receptor (GHRHR) as endogenous GHRH and CJC-1295 / MOD-GRF 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl N-terminal modification. 1. GHRH receptor agonism (Gs / cAMP / PKA / CREB pathway) -… | SLU-PP-332 acts through pan-agonism of the three estrogen-related receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3), a subfamily of orphan nuclear receptors that regulate oxidative metabolism, mitochondrial biogenesis, and exercise-responsive gene expression. The… |
| Half-Life | 8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels) | — |
| Typical Dose Range | 1,000–2,000 mcg (1–2 mg) daily | Research compound — no established human doses. Animal studies: 10-50 mg/kg |
| Dosing Frequency | Once daily subcutaneous injection | — |
| Administration | subcutaneous | — |
| Side Effects | Tesamorelin has a well-characterized side-effect profile from the FDA approval program, which is a significant advantage over non-approved GHRH analogs. Common (10% in Phase 3 trials) - Injection site reactions — erythema, pruritus, pain at site; most frequent… | The side effect profile of SLU-PP-332 in humans is undocumented because no clinical trials have been conducted. Rodent studies report generally acceptable tolerability at doses producing exercise-mimetic metabolic effects, without overt signs of toxicity on… |
| Molecular Weight | 5135.9 Da | 290.3 g/mol |
| Common Vial Sizes | 2mg, 10mg | — |
Price History
3 data points- BM
- Half Nattys
- BHG Labs
Price History
3 data points- Half Nattys
- Ion Peptide
- BHG Labs
Tesamorelin: potential benefits
- Reduction of visceral adipose tissue (~15% at 26 weeks in the pivotal HIV trial; FDA-label indication)
- Reduction of hepatic fat content (NAFLD off-label indication)
- Higher IGF-1 (mean rise of about 81% at 26 weeks in the main Phase 3 trial, PMID 18057338)
- Preserved pulsatile GH release (vs continuous elevation with CJC-1295-DAC)
- Improved body composition (VAT down, lean mass preserved)
- Sustained VAT reduction through 52 weeks with continued dosing
- FDA-approved - the only GHRH secretagogue with that status
SLU-PP-332: potential benefits
- Exercise mimicry without physical exertion
- Enhanced fat oxidation
- Increased mitochondrial biogenesis
- Improved endurance capacity
- Muscle fiber type conversion
- Metabolic health improvement
Frequently asked
What's the difference between Tesamorelin and SLU-PP-332?
Tesamorelin is a growth hormone / igf-1 axis that tesamorelin activates the same ghrh receptor (ghrhr) as endogenous ghrh and cjc-1295 / mod-grf 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl…. SLU-PP-332 is a performance that slu-pp-332 acts through pan-agonism of the three estrogen-related receptors (errα/nr3b1, errβ/nr3b2, errγ/nr3b3), a subfamily of orphan nuclear receptors that regulate oxidative…. The two differ in mechanism, half-life (8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels) vs not reported), and typical dose range.
Which has the longer half-life, Tesamorelin or SLU-PP-332?
Tesamorelin has a half-life of 8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels). SLU-PP-332 has a half-life of not reported. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Tesamorelin or SLU-PP-332?
Lowest listed price on BodyHackGuide: Tesamorelin from $44.99, SLU-PP-332 from $69.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Tesamorelin and SLU-PP-332?
Stacking depends on mechanism overlap, safety profile, and goals. Tesamorelin and SLU-PP-332 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Tesamorelin or SLU-PP-332
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.